Search

Displaying results 2341 - 2350 of 7452 in total
  1. Drug

    beta-Hydroxybutyric acid

    go.drugbank.com/drugs/DB16506
    Investigational

    (completed for type 1 diabetes), and NCT05581043 (completed for type 2 diabetes). … Beta-hydroxybutyrate is being studied in around 230 clinical trials, including NCT06351124 (recruiting for Crohn's disease), NCT05584371 (recruiting for safety and tolerability of exogenous ketosis), NCT04656236

    Categories: Experimental Unapproved Treatments for COVID-19
  2. Drug

    Oxolamine

    go.drugbank.com/drugs/DB13216
    Approved

    Oxolamine is also approved in Taiwan for the treatment of respiratory tract inflamation [L5422].

    Mixtures: KATARIN FORT 650 MG/200 MG/60 MG/4 MG FİLM KAPLI TABLET, 20 ADET
  3. Drug

    Avanafil

    go.drugbank.com/drugs/DB06237
    Approved

    In comparison with other drugs of the same class, it shows greater selectivity for PDE5 over PDE6 than both [sildenafil] and [vardenafil] but less selectivity than [tadalafil], suggesting a relatively

  4. Drug

    Propylhexedrine

    go.drugbank.com/drugs/DB06714
    Approved

    It is used to give temporary relief for nasal congestion from colds, allergic rhinitis, or allergies.

  5. Drug

    Torasemide

    go.drugbank.com/drugs/DB00214
    ApprovedInvestigational

    [A319] Torasemide was first approved for clinical use by the FDA in 1993.[L5257]

    Categories: Antihypertensive Agents Indicated for HypertensionProducts: UNAT COR, TOREM COR
  6. Drug

    Interferon alfacon-1

    go.drugbank.com/drugs/DB00069
    ApprovedWithdrawn

    Interferon alfacon-1 is produced in Escherichia coli (E. coli) cells that have been genetically altered by insertion of a synthetically constructed sequence that codes for Interferon alfacon-1. … Four additional amino acid changes were made to facilitate the molecular construction, and a corresponding synthetic DNA sequence was constructed using chemical synthesis methodology.

  7. Drug

    Bosutinib

    go.drugbank.com/drugs/DB06616
    ApprovedInvestigational

    [A6901,A17961] Bosutinib was first approved by the FDA in 2012 for the treatment of adult chronic, accelerated, or blast-phase Ph+ CML with resistance or intolerance to prior therapy. … [L48436] On September 26, 2023, bosutinib was also approved by the FDA for the treatment of pediatric CML that is newly diagnosed or resistant/intolerant to prior therapy.

  8. Drug

    Besilesomab

    go.drugbank.com/drugs/DB13979
    Approved

    Besilesomab is a mouse monoclonal antibody labelled with the radioactive isotope technetium-99m for determining the location of inflammation/infection in peripheral bone in adults with suspected osteomyelitis … Utilised only as a diagnostic agent, besilesomab is currently approved by the EMEA for marketing and use in various European countries like Italy, France, Germany, Spain, Portugal, Norway, Sweden, the

  9. Drug

    Capreomycin

    go.drugbank.com/drugs/DB00314
    ApprovedInvestigational

    Cyclic peptide antibiotic similar to viomycin. It is produced by Streptomyces capreolus.

    Categories: Antiinfectives for Systemic Use, Drugs for Treatment of Tuberculosis
  10. Drug

    Vadadustat

    go.drugbank.com/drugs/DB12255
    ApprovedInvestigational

    [A244165] A relatively new and alternative treatment option for patients with anemia associated with CKD is the use of small molecule inhibitors of hypoxia-inducible factor prolyl-hydroxylase (HIF-PH … [A244145,A244155] It was first approved in Japan in 2020,[L50371] and in April 2023, it was approved by the EMA for the treatment of symptomatic anemia associated with CKD in adults on chronic maintenance